Congress strips immunity shield from pandemic drug makers, restores right to sue

What it does

This bill repeals two sections of federal law (319F-3 and 319F-4 of the Public Health Service Act) that currently shield pharmaceutical manufacturers and other entities from liability when they develop, distribute, or administer emergency medical countermeasures (drugs, vaccines, devices) during declared public health emergencies under the PREP Act. The repeal restores the right of citizens to sue for injuries caused by these products in federal or state court, effective immediately for pending and future claims.

Why we flagged it

The bill's core function is to eliminate federal immunity for pharmaceutical manufacturers and other entities under the PREP Act, restoring private rights of action for injury claims. This is fundamentally a deregulatory reversal—removing a shield rather than imposing new restrictions.

What the text implies

• Retroactive application to pending claims means manufacturers face immediate exposure to lawsuits filed before enactment, potentially creating a sudden litigation surge and settlement pressure.
• The bill does not establish a statute of limitations or claims procedure, leaving the scope and timeline of potential litigation undefined and potentially unlimited.
• Rescission of the Covered Countermeasure Process Fund (a compensation mechanism) without establishing an alternative remedy may leave injured parties without a streamlined path to recovery.
• Repeal may chill future emergency product development and distribution if manufacturers cannot obtain liability insurance or face prohibitive legal costs, potentially hampering public health response capacity.
• The bill applies only to federal immunity under PREP Act sections 319F-3 and 319F-4, leaving state-level immunity provisions and other federal shields (e.g., under the Federal Tort Claims Act) potentially intact, creating a patchwork of liability exposure.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens gain a concrete legal remedy—the ability to sue for injuries from emergency medical products—that was previously blocked by federal immunity. This restores a fundamental right to seek redress for harm, which strengthens accountability and incentivizes safer product development and distribution practices.

Who stands to gain

• personal injury law firms
• class action attorneys
• litigation finance companies

Named in the bill

Public Health Service Act, PREP Act (Public Law 109-148), Section 319F-3 (42 U.S.C. 247d-6d), Section 319F-4 (42 U.S.C. 247d-6e), Covered Countermeasure Process Fund, Federal Food, Drug, and Cosmetic Act, Section 565 (21 U.S.C. 360bbb-4), Bristol Myers Squibb (BMY), Gilead Sciences (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ)

Where it stands

3 cosponsors: 3 Republicans.

• Jul 15, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jul 15, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.